Efficacy And Safety Of Ritlecitinib In Asian Patients With Alopecia Areata: A Subgroup Analysis Of The ALLEGRO Phase 2b/3 Trial

The ALLEGRO phase 2b/3 trial assessed the efficacy and safety of ritlecitinib, a JAK3 inhibitor, in 186 Asian patients with alopecia areata. The study demonstrated that ritlecitinib significantly improved hair regrowth, with 36.4% to 48.5% of patients achieving a SALT score ≤20 by week 48, depending on the dosage. Improvements were also noted in eyebrow and eyelash regrowth, with up to 71.1% achieving a response by week 48. The safety profile was acceptable, with common adverse events being mild to moderate, such as nasopharyngitis and folliculitis. The study supports ritlecitinib as an effective treatment for alopecia areata in Asian patients, consistent with results from the overall population.